RPG Life Sciences has reported total income of Rs.108.54 crores during the period ended June 30, 2021 as compared to Rs.93.06 crores during the period ended March 31, 2021.

The company reported total income of Rs.92.10 crores during the period ended June 30, 2020.

RPG Life Sciences has posted net profit of Rs.13.58 crores for the period ended June 30, 2021 as against net profit of Rs.6.92 crores for the period ended March 31, 2021.

The company posted net profit of Rs.9.06 crores for the period ended June 30, 2020.

The company has reported EPS of Rs.8.21 for the period ended June 30, 2021 as compared to Rs.5.48 for the period ended June 30, 2020.

Yugal Sikri, Managing Director, RPG Life Sciences Ltd. said, "In Q1 FY22, the overall performance of the Company continued to be strong despite the impact of the second wave of COVID-19 pandemic. Revenue and PBT grew by 18% and 50% respectively Y-o-Y. EBITDA margin retained its upward trajectory growing from 18.9% to 21.6% Y-o-Y.

We continue to be focused on executing our turnaround strategy. On domestic business front, it comprises of 5 initiatives viz. Product portfolio rejuvenation by building chronic and specialty portfolio with new launches; Building our strategic brand assets through diligent life cycle management strategies; Deepening our customer coverage in targeted therapies by expanding our field force and increasing our Share of Voice through innovative digital solutions; Strengthening our Prescription Business model by focusing on all customer, salesforce and patient related initiatives; and Improving profitability by opex control, efficient manufacturing operations and sales hygiene. On international business front, our strategy is to step-wise build up our business profitably with a focus on expanding markets and products with some competitive edge."